In total, 67 NSCLC patients who were EGFR, ALK, and PD-L1 negative, had an ECOG PS of 2, and had multiple metastases including brain metastases received a combination of platinum-based chemotherapy as first-line treatment. The gene discussed is ALK; the disease is non-small cell lung carcinoma.